Estimating Vaccination Effects on COVID-19 outbreak course in Japan

Junko Kurita[1], Tamie Sugawara[2], Yasushi Ohkusa[2]

1) Department of Nursing, Tokiwa University, Ibaraki, Japan

2) National Institute of Infectious Diseases, Tokyo, Japan

Corresponding author: Junko Kurita, kuritaj@tokiwa.ac.jp

ICMJE Statement

Contributors JK was responsible for the coordination of the study and responsible for the data setting. YO developed the model and TS illustrated the results. All authors contributed to the writing of the final manuscript.

Keywords: COVID-19, effective reproduction number, herd immunity, vaccine coverage

Abstract

Background: Japan started vaccinations for COVID-19 in late February, 2021, mainly

using BNT162b2 mRNA COVID-19 Vaccine.

Object: We evaluated COVID-19 vaccination effects on infectiousness in Japan.

Method: The effective reproduction number R(t) was regressed on vaccine coverage

along with data of temperature, humidity, mobility, and countermeasures. We presumed

two definitions for vaccine coverage: at least a single dose with a 12-day delay and a

second dose. The study period was February, 2020 through May 16, 2021.

Results: Estimation results indicate that vaccine coverage significantly and drastically

reduced R(t) for both definitions. Results imply that increased first shot coverage by 1%

point decreased R(t) by 0.5 with a 12 day delay. Moreover, increased second shot

coverage by 1% point, decreased R(t) by 1 immediately.

Discussion and Conclusion: Vaccination effects might be stronger because the periods

when vaccination was started and rapid spread coincide with a decreasing phase of R(t).

Introduction

Wide coverage of COVID-19 vaccination has changed the outbreak situation in European countries and US. Unfortunately, vaccination started only in February, 2021 in Japan, among the latest of starting dates in economically developed countries. As of June 6, 2021, the rate of completion for two shots was only about 3% in Japan (Figure 1) [1,2].

Fortunately, prevalence of COVID-19 has been much lower in Japan than in European countries and the US. For instance, prevalence in the US was approximately 10% as of June 6, 2021, but only 0.6% in Japan, which had used no lock down. Although reasons for such differences remain unknown, vaccine efficacy in Japan might be different from efficacy in US and European countries.

Moreover, vaccination has provided not only personal protection, but also herd immunity to unvaccinated persons. The former was investigated in clinical trials [3], but the latter might depend on the surrounding society. Therefore, the present study examined vaccine effectiveness, including herd immunity in Japan. To measure the vaccine effectiveness, we estimated the effects of vaccine coverage on SARS-CoV-2 infectiousness in Japan.

As countermeasures against the COVID-19 outbreak in Japan, school closure and voluntary event cancellation were adopted from February 27, 2020 through the end of

March. Large commercial events were cancelled. Subsequently, a state of emergency was declared for April 7 through 25 May, stipulating voluntary restrictions against leaving home. Consumer businesses such as retail shops and restaurants were shut down. During this period, the first peak of infection was reached on April 3. Infections subsequently decreased until July 29. The so-called "Go To Travel Campaign" (GTTC) started on July 22 as a 50% subsidized travel program aimed at supporting sightseeing businesses with government-issued coupons for use in shopping at tourist destinations. It was expected that the campaign might expand the outbreak. Thereafter, GTTC continued to the end of December, by which time a third wave of infection had emerged. The third wave in December, which was larger than either of the preceding two waves, reached its highest peak at the end of December. Therefore, GTTC was inferred as the main reason underlying the third wave [4].

To force the third wave lower, the second emergency status was declared on January 8, 2021 to March 15, 2021. However, the fourth wave emerged, probably because of the spread of variant strains at the end of February. Moreover, to support the hosting of the Olympics and Paralympics games in Tokyo in July, a third emergency state was declared on April 25, 2021.

Nevertheless, although results have been mixed, some results of earlier studies suggest that COVID-19 might be associated with climate conditions [5–8]. If that were true for Japan, then GTTC might not be the main reason for the third wave.

Moreover, mobility was inferred as the main cause of the outbreak dynamics, at least in the first wave in Japan [9] and throughout the world [10–13]. This study was conducted to estimate vaccine coverage effects on SARS-CoV-2 infectiousness for the outbreak in Japan.

Methods

The numbers of symptomatic patients reported by the Ministry of Health, Labour and Welfare (MHLW) for January 14 – May 16, published [14] as of June 6, 2021 were used. Some patients were excluded from data for Japan: those presumed to be persons infected abroad or infected as Diamond Princess passengers. Those patients were presumed not to represent community-acquired infection in Japan. For some symptomatic patients with unknown onset dates, we estimated onset dates from an empirical distribution with duration extending from onset to the report date among patients for whom the onset date had been reported.

Onset dates among patients who did not report this information and reporting delay

were adjusted using the same procedures as those used for our earlier research [15,16].

As described hereinafter, we estimated the onset dates of patients for whom onset dates

had not been reported. Letting $f(k)$ represent this empirical distribution of incubation

period and letting N_t denote the number of patients for whom onset dates were not

published and available at date t, then the number of patients for whom the onset date

was known is t-1. The number of patients with onset date t-1 for whom onset dates were

not available was estimated as $f(1)N_t$. Similarly, patients with onset date t-2 and for

whom onset dates were not available were estimated as $f(2)N_t$. Therefore, the total

number of patients for whom the onset date was not available, given an onset date of s,

was estimated as $\Sigma_{k=1}f(k)N_s+k$ for the long duration extending from s.

Moreover, the reporting delay for published data from MHLW might be

considerable. In other words, if $s+k$ is larger than that in the current period t, then $s+k$

represents the future for period t. For that reason, N_{s+k} is not observable. Such a

reporting delay engenders underestimation of the number of patients. For that reason, it

must be adjusted as $\Sigma_{k=1}^{t-s}f(k)N_s+k / \Sigma_{k=1}^{t-s}f(k)$. Similarly, patients for whom the onset

dates were available are expected to be affected by the reporting delay. Therefore, we

have $M_{s|t} / \Sigma_{k=1}^{t-s}f(k)$, where $M_{s|t}$ represents the reported number of patients for whom

onset dates were period s as of the current period t.

We defined $R(t)$ as the number of infected patients on day t divided by the number of patients who were presumed to be infectious. The number of infected patients was calculated from the epidemic curve by the onset date using an empirical distribution of the incubation period, which is $\Sigma_{k=1}f(k)E_{t+k}$, where E_t denotes the number of patients for whom the onset date was period t. The distribution of infectiousness in symptomatic and asymptomatic cases $g(k)$ was assumed to be 30% on the onset day, 20% on the following day, and 10% for the subsequent five days [17]. Then the number of infectiousness patients was $\Sigma_{k=1}g(k)E_{t-k}$. Therefore, R(t) was defined as

$\Sigma_{k=1}f(k)E_{t+k}/\Sigma_{k=1}g(k)E_{t-k}$.

We use average temperature and relative humidity data for Tokyo during the day as climate data because national average data were not available. We obtained data from the Japan Meteorological Agency (https://www.data.jma.go.jp/gmd/risk/obsdl/index.php). We identified several remarkable countermeasures in Japan: two emergency status declarations, GTTC, and school closure and voluntary event cancellation (SCVEC). The latter, SCVEC, extended from February 27 through March: this countermeasure required school closure and cancellation of voluntary events, and even of private meetings. Then the first state of emergency was declared April 7. It ceased at the end of May. It required voluntary

restriction against going out, school closures, and shutdown of businesses. To subsidize

travel and shopping at tourist destinations, GTTC started on July 22. It was halted

temporarily at the end of December. The second state of emergency was declared on

January 7, 2021 for the 11 most affected prefectures. This countermeasure required

restaurant closure at 8:00 p.m., with voluntary restrictions against going out, but did not

require school closure. It continued until March 21, 2021. The third state of emergency

was declared on April 25, 2021 for four prefectures: Tokyo, Osaka, Hyogo, and Kyoto.

Later, the application areas were extended gradually, but never covered the entirety of

Japan.

To clarify associations among R(t) and vaccine coverage as well as climate,

mobility, and countermeasures, we regressed the daily R(t) on dummy variables for

daily vaccine coverage, daily climate, mobility, and countermeasures using ordinary

least squares regression. Temperatures were measured in degrees Celsius, humidity, and

mobility as percentages in regression, not as standardized. When some variables were

found to be not significant, we excluded them and estimated the regression line again. If

some variables were not significant in the full specification estimation, then we

estimated them again stepwisely without those non-significant variables.

We examine two definitions for vaccine coverage: rate of receiving at least a single

dose with a 12 day delay and the completion rate of the second dose. Delay in the former was the response period for increasing antibody [18]. If a vaccine protects the recipient from infection perfectly, the estimated coefficient of vaccine coverage should be 0.01 if one assumes an average of $R(t)$ with no vaccination in the study period. That means that increasing vaccine coverage by 1% point was expected to reduce $R(t)$ by 1% point. If the estimated coefficients of vaccine coverage were smaller than 0.01, then it might reflect imperfect personal prevention. Conversely, if the estimated coefficients of vaccine coverage were smaller than 0.01, it might mean that herd immunity contributed to prevention from infection among non-recipients.

We also examined another delay in vaccine coverage to verify robustness. We found 14 days of delay in the first dose and 7 days of delay in the second dose. We adopted 5% as the level at which to infer significance.

Results

Figure 2 presents an empirical distribution of the duration of onset to reporting in Japan. The maximum delay was 31 days. Figure 3 presents an empirical distribution of incubation periods among 91 cases for which the exposed date and onset date were published by MHLW in Japan. The mode was six days. The average was 6.6 days. The

calculated $R(t)$ is shown in Figure 1.

Table 1 presents estimation results of two definitions of vaccine coverage to $R(t)$. In both definitions, climate conditions and the third emergency status were not significant in specifications (1) and (3). Therefore, we deleted these variables as explanatory variables. All remaining variables in the specification (2) and (4) were significant.

Mobility was positive and significant. The first two emergency status periods and GTTC were found to be negative and significant. However, SCVEC was found to be significant and positive. Vaccine coverage was significantly negative, as expected. However, its estimated coefficients were approximately 0.5 in the specification (2) and one in the specification (4). These were 50–100 times larger than expectations from personal prevention.

Another definition adopted for the delay period until sufficiently increasing antibodies to protect from infection yielded similar results to those presented above. The estimated coefficients for vaccine coverage were -0.44365 (p-value was 0.000) for the first doze with 14 days delay and   -0.97141 (0.000) for the second doze with 7 days delay.

Discussion

Estimation results showed that vaccine coverage was significantly negative and that the estimated coefficients were far larger than expected from personal prevention. That finding might mean that herd immunity strongly reduced $R(t)$. However, it might be biased by a shorter period with vaccine in Japan because the period at which vaccination was started and spread rapidly coincided with the decreasing phase of $R(t)$. Vaccination effects might more strongly incorporate another effect to reduce $R(t)$, but might not be included as explanatory variables.

Because we presumed a linear function of vaccine coverage and presumed that the estimated coefficients were larger than expected, the predicted $R(t)$ is expected to be negative. That result was inconsistent with definition of $R(t)$. Therefore, such a linear association should disappear with increased vaccine coverage. This nonlinearity might also diminish herd immunity effects.

The third emergency status was not significant. That finding is probably attributable to overlap of the period of the third emergency and initiation of the vaccine campaign. Consequently, multicollinearity might occur among these two variables. Actually, if vaccine coverage is dropped in specification (1) or (3), then the estimated coefficient of the third emergency status was -0.89263; its p value was 0.000. The value was comparable to the first two emergency status periods.

The present study has some limitations. First, as described above, effects of vaccine coverage and estimated herd immunity might be overestimated. Accumulation of the data will probably resolve this problem.

Secondly, readers must be reminded when interpreting the obtained results that our obtained results do not indicate causality. This study demonstrated that some association exists among vaccine coverage and infectiousness. That finding does not necessarily mean that vaccine coverage reduces infectiousness: it might imply that lower infectiousness, for instance, an effective reproduction number being smaller than one, induces people to approach vaccination more enthusiastically.

Conclusion

Because the period when vaccination was started and spread rapidly coincides closely with the decreasing phase of $R(t)$, vaccination effects might be estimated as stronger than they actually were. Accumulation of data and longer periods of data might decrease that misleading effect.

The present study is based on the authors' opinions: it does not reflect any stance or policy of their professionally affiliated bodies.

Acknowledgments

We acknowledge the great efforts of all staff at public health centers, medical institutions, and other facilities who are fighting the spread and destruction associated with COVID-19.

Ethical considerations

All information used for this study was published data on the web were used. There is therefore no ethical issue related to this study.

Competing Interest

No author has any conflict of interest, financial or otherwise, to declare in relation to this study.

Reference

1. Prime Minister and his Cabinet. Novel Coronavirus Vaccines.

    https://www.kantei.go.jp/jp/headline/kansensho/vaccine.html (in Japanese)

    [accessed on June 15, 2021]

2. Japan Ministry of Health, Labour and Welfare. Situation of vaccine coverage for

    COVID-19.

    https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/vaccine_sesshujisseki.html   (in

    Japanese) [accessed on June 15, 2021]

3. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL,

    Perez Marc G, Moreira ED, Zerbini C, Bailey R, Swanson KA, Roychoudhury S,

    Koury K, Li P, Kalina WV, Cooper D, Frenck RW Jr, Hammitt LL, Tureci O, Nell

    H, Schaefer A, Unal S, Tresnan DB, Mather S, Dormitzer PR, ?ahin U, Jansen KU,

    Gruber WC; C4591001 Clinical Trial Group. Safety and Efficacy of the BNT162b2

    mRNA Covid-19 Vaccine. N Engl J Med. 2020;383:2603-15.

4. Japan Times. Japan to suspend Go To Travel program nationwide from Dec. 28 to

    Jan. 11

    https://www.japantimes.co.jp/news/2020/12/14/national/suga-go-to-travel-coronavi

    rus/ [accessed on June 5,2021]

5. Shi P, Dong Y, Yan H, Zhao C, Li X, Liu W, He M, Tang S, Xi S. Impact of temperature on the dynamics of the COVID-19 outbreak in China. Sci Total Environ. 2020 ;728:138890.

6. Tobias A, Molina T. Is temperature reducing the transmission of COVID-19 ? Environ Res. 2020 ;186:109553.

7. Yao Y, Pan J, Liu Z, Meng X, Wang W, Kan H, Wang W. No association of COVID-19 transmission with temperature or UV radiation in Chinese cities. Eur Respir J. 2020 ;55:2000517.

8. Walrand S. Autumn COVID-19 surge dates in Europe correlated to latitudes, not to temperature-humidity, pointing to vitamin D as contributing factor. Scientific Reports volume 11, Article number: 1981 (2021) Cite this article

https://www.nature.com/articles/s41598-021-81419-w

9. Kurita J, Sugishita Y, Sugawara T, Ohkusa Y. Mobility data can reveal the entire COVID1-19 outbreak course in Japan. JMIR Public Health & Surveillance 2021,7.

https://publichealth.jmir.org/2021/2/e20335

10. Bergman N, Fishman R. Mobility Reduction and Covid-19 Transmission Rates.**doi:**

https://doi.org/10.1101/2020.05.06.20093039

11. Flaxman S, Mishra S, Gandy A, Unwin HJT, Mellan TA, Coupland H, Whittaker C,

Zhu H, Berah T, Eaton JW, Monod M, Imperial College COVID-19 Response Team; Ghani AC, Donnelly CA, Riley S, Vollmer MAC, Ferguson NM, Okell LC, Bhatt S. Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe. Nature 2020 ;584(7820):257-61. doi: 10.1038/s41586-020-2405-7.

12. Li Y, Campbell H, Kulkarni D, Harpur A, Nundy M, Wang X, Nair H, for theUsher Network for COVID-19 Evidence Reviews (UNCOVER) group. The temporal association of introducing and lifting non-pharmaceutical interventions with the time-varying reproduction number (R) of SARS-CoV-2: a modelling study across 131 countrie**s.** *Lancet Infect Dis* 2021; 21: 193–202 DOI:https://doi.org/10.1016/S1473-3099(20)30785-4? https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30785-4/fulltext

13. Larrosa JMC. SARS-CoV-2 in Argentina: Lockdown, mobility, and contagion. J Med Virol 2020. doi: 10.1002/jmv.26659. https://onlinelibrary.wiley.com/doi/10.1002/jmv.26659

14. Japan Ministry of Health, Labour and Welfare. Press Releases. https://www.mhlw.go.jp/stf/newpage_10723.html (in Japanese) [accessed on June 6, 2021].

15. Kurita J, Sugawara T, Ohkusa Y. Estimated effectiveness of school closure and voluntary event cancellation as COVID-19 countermeasures in Japan. J Infect Chemother 2021, 27:62-4.   doi: 10.1016/j.jiac.2020.08.012.

16. Sugishita Y, Kurita J, Sugawara T, Ohkusa Y. Effects of voluntary event cancellation and school closure as countermeasures against COVID-19 outbreak in Japan. Plos one 2020. https://doi.org/10.1371/journal.pone.0239455

17. Kimball A, Hatfield KM, Arons M, James A, Taylor J, Spicer K, Bardossy AC, Oakley LP, Tanwar S, Chisty Z, Bell JM, Methner M, Harney J, Jacobs JR, Carlson CM, McLaughlin HP, Stone N, Clark S, Brostrom-Smith C, Page LC, Kay M, Lewis J, Russell D, Hiatt B, Gant J, Duchin JS, Clark TA, Honein MA, Reddy SC, Jernigan JA; Public Health ? Seattle & King County; CDC COVID-19 Investigation Team. Asymptomatic and Presymptomatic SARS-CoV-2 Infections in Residents of a Long-Term Care Skilled Nursing Facility - King County, Washington, March 2020. Morb Mortal Wkly Rep. 2020 Apr 3;69(13):377-381. doi: 10.15585/mmwr.mm6913e1.

18. Hunter PR, Brainard J. Estimating the effectiveness of the Pfizer COVID-19 BNT162b2 vaccine after a single dose. A reanalysis of a study of 'real-world' vaccination outcomes from Israel.

Figure 1: Effective reproduction number and vaccine coverage by two definitions.

vaccine coverage (%)   R(*t*)

(date)

Note: Line shows the effective reproduction number measured at the right-hand side. Red * denotes vaccine coverage defined by the first dose with 12 days delay. Green + denotes vaccine coverage defined by the second dose. Two vaccine coverages were measured at the left-hand side. Because daily vaccine coverage were not reported in weekend and national holidays, data of vaccine coverages were missing in these days.

Figure 2: Empirical distribution of duration from onset to report by MHLW, Japan.

(%)

Note: Bars represent the probability of duration from onset to report based on 657

patients for whom the onset date was available in Japan. Data were obtained from

MHLW, Japan.

Figure 3: Empirical distribution of the incubation period published by MHLW, Japan.

(%)

(days)

Notes: Bars show the distribution of incubation periods for 91 cases for which the exposure date and onset date were published by MHLW, Japan. Patients for whom incubation was longer than 14 days are included in the bar shown for day 14.

Table 1: Estimation results of R(t) on vaccine coverage with the climate condition,

mobility, and countermeasures

Definition of vaccine coverage	First dose				Second dose			
Specification	(1)		(2)		(3)		(4)	
Explanatory variable	Estimated coefficient	p-value	Estimated coefficient	p-value	Estimated coefficient	p-value	Estimated coefficient	p-value
Temperature	-0.00517	.262	N.A.	N.A.	-0.00550	.232	N.A.	N.A.
Humidity	-0.00067	.713	N.A.	N.A.	-0.00099	.589	N.A.	N.A.
Mobility	0.00963	.000	0.00959	.000	0.00970	.000	0.00949	.000
SCVEC	0.79998	.000	0.84151	.000	0.77722	.000	0.83467	.000
1st Emergency status	-0.78041	.000	-0.77709	.000	-0.79551	.000	-0.78830	.000
GTTC	-0.86188	.000	-0.87127	.000	-0.87910	.000	-0.87752	.000
2nd Emergency status	-0.98200	.000	-0.92334	.000	-1.01506	.000	-0.937285	.000
3rd Emergency	0.18561	.552	N.A.	N.A.	0.59776	.081	N.A.	N.A.

status

Vaccine Coverage (%)	-0.50658	.000	-0.44268	.000	-1.00610	.000	-0.70595	.000
Constant	0.96099	.000	0.82785	.000	0.99962	.000	0.84554	.000
Adjusted R^2	0.5355		0.5361		0.5431		0.5423	
Number of observations			436				431	

Note: The dependent variable was R(t): GTTC stands for "Go To Travel Campaign";

SCVEC denotes school closure and voluntary event cancellation. Sample period was

from February 1, 2021 through May 16, 2021 as of June 6, 2021.